CJC-1295 & Ipamorelin Blend

Related by research scope · open each to compare

Regulatory detail for this region is not available in the current seed.

Confirmed high-severity market-integrity event (enforcement / recall / counterfeit)

Transparent blend · bci-1.0 · never paid-placement

Primary name

CJC-1295 & Ipamorelin Blend

Sequence not available in current seed.

• GHS hazard class on file
• PPE & spill response
• Disposal guidance
• Not-for-human-consumption posture

Short-acting synthetic GHRH(1-29) analog, chemically identical to CJC-1295 apart from lacking the C-terminal drug affinity complex (DAC) moiety, giving it a much shorter circulating exposure than the DAC form and no peer-reviewed human pharmacokinetic characterization to date.

Like CJC-1295, this analog is designed to bind GHRH receptors on pituitary somatotrophs and stimulate pulsatile growth hormone release, using the same set of proteolysis-resistant amino-acid substitutions relative to native human GHRH. Because it lacks the DAC maleimide group, it is not expected to form the covalent albumin adduct that gives the DAC form its multi-day exposure; without that depot mechanism its circulating half-life is expected to more closely resemble unmodified GHRH(1-29) analogs. A 2026 peer-reviewed narrative review (Dominikowski et al., Front Endocrinol, PMID 42395176) states directly that 'CJC-1295 without DAC' remains essentially uncharacterised in the peer-reviewed human literature: no controlled clinical studies have directly evaluated this specific compound in humans, and claims about physiologic GH pulsatility or body-composition effects are extrapolated from related unmodified GHRH(1-29) analogs (e.g., sermorelin) and non-academic sources rather than from direct evidence on this molecule.

Molar mass

3367.9 g/mol

Synthetic pentapeptide GHS-R1a agonist that triggers pulsatile GH release with high selectivity; minimal cortisol or prolactin co-elevation. Research use only.

Ipamorelin binds and activates GHS-R1a (the ghrelin receptor), a Gq/11-coupled GPCR expressed predominantly on anterior pituitary somatotrophs and hypothalamic arcuate nucleus neurons. Receptor engagement activates phospholipase C, generates inositol trisphosphate, mobilises intracellular calcium, and triggers exocytosis of stored growth hormone. Ipamorelin acts synergistically with endogenous GHRH to amplify pulsatile GH release while also partially suppressing somatostatin tone in the hypothalamus. A key pharmacological distinction from other GHRPs is its high receptor selectivity: at physiological concentrations it does not meaningfully activate adrenocortical or lactotroph pathways, so cortisol and prolactin co-elevation are minimal compared with GHRP-2 or GHRP-6.

Molar mass

711.9 g/mol

How much research exists, and of what maturity — never a verdict on whether it works.

Reading the evidence

• Evidence quality and gaps vary by application — see the cited grades above.
• Indexed-article counts span all evidence tiers, not only completed human trials.
• No first-party human-dosing, efficacy, or benefit claims are made here.

Key reviews & evidence-gap sources

• Raun et al. 1998, Eur J Endocrinol: Ipamorelin, the first selective growth hormone secretagogue — Primary discovery paper (Novo Nordisk). Defines Ipamorelin as a GHS-R1a agonist that releases GH without significant ACTH, cortisol or prolactin. Animal-model work.
• Teichman et al. 2006, JCEM: CJC-1295 prolonged GH/IGF-1 stimulation in healthy adults — The load-bearing human PK/PD study of CJC-1295, but of the DAC form (albumin-bound, half-life 5.8-8.1 days), NOT the no-DAC / Mod GRF 1-29 molecule used in blends. Phase 1, randomized, placebo-controlled, subcutaneous. PK/PD, not an efficacy RCT.
• Ionescu & Frohman 2006, JCEM: GH pulsatility persists during continuous CJC-1295 stimulation — Second human CJC-1295 (DAC) study; GH secretion stays pulsatile under sustained GHRH-analog exposure.
• Beck et al. 2014, Int J Colorectal Dis: Ipamorelin proof-of-concept RCT for postoperative ileus — The only COMPLETED and peer-reviewed human RCT of either component. Ipamorelin IV for a GI-motility indication in bowel-resection patients (NCT00672074). NOT the blend and NOT a GH/body-composition endpoint. Program was not advanced.
• Sigalos & Pastuszak 2018, Sex Med Rev: The Safety and Efficacy of Growth Hormone Secretagogues — Peer-reviewed review covering CJC-1295 and Ipamorelin; concludes GH secretagogues are generally well tolerated in short trials but that efficacy and long-term safety (glucose, cancer-risk questions) are unresolved.

No registered human trials found for this compound.

Status

No registered trials found

Dominant research route: Subcutaneous is the dominant route across both the component human PK literature (CJC-1295 DAC, Teichman 2006, SC) and community use of the blend; intravenous appears in the Ipamorelin postoperative-ileus program and early PK work. No route has been formally studied for the CJC-1295 plus Ipamorelin COMBINATION.

The route of the pivotal human CJC-1295 (DAC) PK studies (Teichman 2006, healthy adults) and the standard route for Ipamorelin in animal GH-response work; also the overwhelmingly dominant community-reported route for the blend. No PK study of the combination by any route.

Bioavailability: Component human PK exists for CJC-1295 DAC given SC (dose-dependent GH rise for 6+ days, IGF-1 for 9-11 days, half-life 5.8-8.1 days); note that is the DAC form, not the no-DAC molecule used in blends. No SC PK for the no-DAC form or for the combination.

Layer-A pharmacokinetics are component-only (CJC-1295 DAC in humans; Ipamorelin in animals); blend-level SC use is community-reported. No human dosing implied.

The route in the Ipamorelin postoperative-ileus program (Helsinn Phase 2, IV, NCT00672074, completed 2009) and in early Ipamorelin / GHRH-analog PK work. Animal plus component-human; not a combination study.

Bioavailability: 100% bioavailable by definition; used in controlled clinical infusion settings for Ipamorelin. Both peptides have short plasma half-lives (Ipamorelin roughly 2 h; Mod GRF 1-29 roughly 30 min).

Component Ipamorelin IV data, for a GI-motility indication, not the blend and not a GH/body-composition endpoint.

A minor community-reported route for the blend; no dedicated human IM pharmacokinetic study for either component.

Bioavailability: No published IM PK/bioavailability data for either peptide. IM absorption is unquantified.

Occasionally described in community reports; kinetics not established in the literature. No human dosing implied.

Marketed by some vendors as nasal sprays; no published intranasal pharmacokinetic study for either CJC-1295 or Ipamorelin. Predominantly community-reported.

Bioavailability: No intranasal PK/bioavailability data. Peptides of this size generally show poor nasal bioavailability; the nasal route is not demonstrated for either component.

Largely a marketed / anecdotal route; systemic delivery is unverified for these peptides.

Not an established systemic route. No oral pharmacokinetic study exists for either component; both are injectable peptides degraded by gastrointestinal proteases.

Bioavailability: Negligible expected oral systemic bioavailability; unlike BPC-157 neither peptide has a documented gastric-stability profile. Oral absorption has never been quantified for either molecule.

Whether any meaningful amount reaches systemic circulation orally is unproven and pharmacologically unlikely. No human oral dosing implied.

Animal & human figures are kept visibly separate so studied animal doses are never misread as human guidance.

Sorted A–Z by vendor — never by price

Weekly median $/mg from the live vendor crawl.

Researched storefront prices, bucketed

p25 $5.00 · median $6.50 · p75 $8.50 · 11 researched vendors

Legit, COA-backed band: $5.00–$8.50/mg.

Value rule: don't just buy the cheapest — a price under $3/mg is a red flag. Pair price with COA and independent-test grade.

Estimated cost of research (10 mg)

Vial (best researched price)

$47

Bacteriostatic water (generic estimate)

$6

Syringes / supplies (generic estimate)

$12

What each test proves — general guidance, plus this compound's researched purity data

Purity on the current market (researched)

Wide and bimodal. Reputable research-market blend vials test near label (e.g. a Peptidology CJC-1295/Ipamorelin 5mg/5mg lot at 99.33% HPLC-UV; multiple vendors publish Janoshik COAs at >=99%). The market tail is severe: the Finnrick aggregate for CJC-1295 spans 1.69% to 100.00% purity across 238 published results / 46 vendors, with advertised quantity diverging by up to +/-100% versus label. Blends carry a characteristic added failure mode: per-component underfill (usually the pricier CJC-1295 shorted while Ipamorelin is nearer spec), which a single combined-mass COA can hide.

Independent labs cited for this compound

Unlike most research peptides, CJC-1295 (including the CJC-1295/Ipamorelin blend) DOES have FDA drug recalls, but every one is a COMPOUNDING-PHARMACY sterility recall (Class II, 'lack of assurance of sterility'), not a purity/underdosing recall of the grey research-chem channel. Verified via the openFDA drug-enforcement database (recall numbers D-0475-2025, D-0109-2022, D-0720-2020). No recall of a research-labeled (RUO) CJC-1295 or blend product was found: FDA acts on that channel via warning letters and import detention, not Class recalls.

Buyer red-flag checklist

• One combined COA for the blend instead of per-component, lot-matched HPLC purity + quantity: a single total-mass number can hide one peptide being underfilled.
• No LC-MS / HR-MS identity on the COA: CJC-1295 (Mod GRF 1-29) cannot be distinguished from cheaper GHRH analogs (sermorelin, plain GRF 1-29) or from the long-acting DAC version by purity alone. (A documented sermorelin-for-CJC substitution case was NOT confirmed in this research, so this is an analytical risk, not a proven event.)
• 'no DAC' vs DAC ambiguity: a product sold as CJC-1295 that is actually CJC-1295 DAC (or vice versa) has different pharmacology; only labeling/identity testing tells them apart.
• Injectable blend with no endotoxin (LAL) or sterility data: sterility failure is the exact cause behind every FDA recall of these products.
• COA report/task ID does not resolve in the lab's public database, or the vial lot doesn't match the lot on the COA (a reused 'showcase' certificate).
• Blend priced far below the market median for the combined mg: consistent with an underfilled or off-spec component.
• Human-dosing / anti-aging / 'GH pulse' benefit marketing on a 'research use only' site: the pattern drawing FDA warning letters.

GMP vs research-grade: the chemistry (SPPS + HPLC + MS) is identical — the difference is the quality system.

Underdosing / mislabeling: Provisional estimate, not a published pass/fail rate. Finnrick's CJC-1295 quantity distribution shows frequent, severe underfills (up to +/-100% off advertised). The blend-specific risk is per-component underdosing and cheaper GHRH-analog substitution (see redFlags). A widely-repeated 'Janoshik: 43% of 2024 peptides failed label purity' figure could NOT be confirmed against a primary lab publication and is treated as unverified. Treat 0.25 as a directional tail-risk estimate pending the live crawler or a primary aggregate.

• The peptide-relevant FDA import controls are Import Alert 66-41 (detention-without-physical-examination of unapproved new drugs, which covers peptides marketed as research chemicals, including CJC-1295 and Ipamorelin) and, for GLP-1 APIs, Import Alert 66-80 'Green List' (19 Sep 2025), which is GLP-1-focused context rather than CJC/Ipamorelin-specific. An RUO label is not an import exemption: CBP judges actual intended use.66-41 (unapproved new drugs) + 66-80 (GLP-1 Green List)
• An RUO label is not an import exemption — CBP judges actual intended use.
• Lyophilized powder is ambient-stable in transit; temperature control needed for > 7-day transit.
• US-warehouse vendors dodge import scrutiny — they cost more but ship more reliably.

Every item dated & sourced

Both prohibited AT ALL TIMES (in- and out-of-competition) on the WADA Prohibited List under Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), growth-hormone releasing factors: CJC-1295 is named as a GHRH analogue, and Ipamorelin as a growth-hormone secretagogue/GHRP. The CJC-1295 + Ipamorelin combination is therefore doubly prohibited; both no-DAC and DAC CJC-1295 are banned. No approved human therapeutic use, so a Therapeutic Use Exemption is not realistically available. (Contrast BPC-157, which is not enumerated under S2 and is generally treated under S0, Non-Approved Substances.)

No granted patents identified in current seed. Composition-of-matter coverage is limited given the peptide's synthetic origin.

• IACUC / IRB research context
• RUO buyer responsibilities & documentation
• Veterinary / alternative-use where lawful
• Jurisdiction-aware "who may lawfully obtain"

What people discuss

Reported concerns — discussion, not established effects

Reading caveats

• Survivorship / positivity bias: dramatic recomp and deep-sleep transformations are over-shared
• Affiliate / 'best blend vendor' SEO content pollutes any automated tone read
• Influencer amplification skews framing positive vs the thin human evidence for this stack
• Placebo / concurrent-substance confounding (training, diet, TRT, other peptides stacked) inherent to anecdotes
• Negativity bias in bad-batch and substitution threads
• Clinic / telehealth 'before & after' marketing resurfacing as apparent community experience

Manually researched from reddit, youtube, bluesky— theme weights are research estimates, not live counts; aggregated & de-identified. No individual posts, quotes, or usernames are ever shown.

Relative research / market volume — populated once the activity stream is wired

Inline tooltips for lyophilized, RUO, EU/mg, SPPS, 503A and more.

Toggle plain-language ↔ scientific in the header.

• How to read a COA
• Free base vs acetate
• Understanding evidence grades

A research blend combining the GHRH analog CJC-1295 with the growth-hormone secretagogue ipamorelin. US regulatory status: Research use only. Research use only.

Emitted as JSON-LD: ChemicalSubstance · BreadcrumbList · FAQPage.

• Price-drop & back-in-stock alerts
• Regulatory-change email digest
• Print / share this datasheet